Adage Capital Partners GP L.L.C. decreased its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 6.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 183,161 shares of the company's stock after selling 12,500 shares during the quarter. Adage Capital Partners GP L.L.C. owned 0.09% of Cencora worth $41,153,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in COR. JFS Wealth Advisors LLC boosted its position in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in Cencora during the 4th quarter worth $30,000. Kentucky Trust Co bought a new stake in shares of Cencora in the 4th quarter worth $33,000. Householder Group Estate & Retirement Specialist LLC raised its holdings in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co boosted its holdings in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on COR shares. Morgan Stanley set a $288.00 target price on shares of Cencora in a research report on Tuesday, April 15th. Evercore ISI lifted their price target on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Bank of America upped their price objective on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $284.55.
Check Out Our Latest Analysis on COR
Cencora Price Performance
COR opened at $281.89 on Friday. The firm has a 50-day moving average price of $267.20 and a 200-day moving average price of $248.71. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market capitalization of $54.66 billion, a price-to-earnings ratio of 40.10, a PEG ratio of 1.31 and a beta of 0.55.
Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.78%. Cencora's dividend payout ratio (DPR) is 31.29%.
Insiders Place Their Bets
In other news, CEO Robert P. Mauch sold 4,970 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. The trade was a 8.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock worth $13,580,967 in the last quarter. 10.80% of the stock is owned by company insiders.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
